Reez Mash 🇺🇸

@BiotechXGuru On the bright side at least we know the loser mgmt team isn’t selling shares. They are tapped out !! lol

$REPL spikes and $IOVA tanks ! REPL still seems like a threat to IOVA

@kainvests Well now we know why the stock tanked from over $5 and how over 25 million shares traded on the day Repl was rejected. If we had a better management team the stock would be $8+ easy right now. Losers like to lose and these guys are the absolute worse. Ugh

$IOVA Yesterday, Iovance filed a PRE 14A form (ir.iovance.com/static-files/3…) as a notice for the Annual Meeting of Stockholders, scheduled for June 10, at 11:00h local time. Now let's do some numbers and extract some meaningful conclusions on where we stand shares-wise and what Iovance's decisions may hint regarding which strategic pathway Iovance is most likely to follow: going solo or a buyout. 🧮 Let's start with some maths! According to this filing, as of April 15 2026, Iovance had 446,502,396 shares outstanding. Remember that the 10-K filed on February 13, 2026, just 61 days earlier, stated 411,961,607 shares outstanding (source: ir.iovance.com/node/15616/html), so that's 34.5M new shares created. These shares are coming from the ATM or At-the-market facility, which allows Iovance to sell new shares quietly, directly into the stock market, day by day, at whatever the current price is. In the last ≈ 12 months, 112.6 million shares have been created. In percentage terms: 33.7% dilution in ≈ a year. Do take into account that a smaller portion of new shares comes from routine sources: employee stock options being exercised, restricted stock units vesting, and employee share purchase plans. For a company this size, that typically accounts for 5–10 million shares per year. The Proposal 6 section of the PRE 14A form states that shareholders will vote on whether to increase the total number of shares Iovance is legally allowed to create: from 500 million to 650 million. That creates 150 million new shares that they may choose to raise or not. At $3.80, fully using all of that would raise approximately $570 million. We expect the stock price to rise with quarter-over-quarter improvement and clinical data updates. We may have positive news from Australia as well; we shall see. While it is frustrating that dilution is on the table and Iovance seems to have overpromised and underdelivered in their commitment to prioritise stakeholder value and explore alternative funding methods, the priority is getting us to the finish line. Whether they may tap the ATM or not, expanding it was a must-do for a company in their situation. 👩🏻‍💼👨🏻‍💼 Something revealing that can be extracted from Page 24 Director Compensation section and subsequent pages is the fact that management voluntarily changed their own pay formula: Instead of a fixed dollar amount, they switched to a fixed percentage of shares outstanding: 0.142% of the total share count, split among all eligible directors. Total director equity pool for 2025: 472,825 shares across all directors. Under the old system at $2.58, each director would have received roughly 165,000 shares. Under the new system, they received 67,546 shares each. They voluntarily took less than half to avoid taking a windfall from a price they clearly believe is temporarily depressed. You may have also noticed that the board will vote on renewing Fred for one more year. For a moment, I thought: “Oh, maybe that signals a buyout?” Unfortunately, it doesn’t! This is the same timeframe for which he is renewed every year. ♟️ So, what does this tell us about a potential going solo or buyout out scenario? It seems that Iovance is executing an independent path to NSCLC approval, because that is what maximises the eventual sale price. It seems management wants to get Iovance to a position of strength and perhaps sell post a potential NSCLC FDA approval, as expected and hoped by most of us in the StockTwits community. But remember, a buyout will get us high returns quicker; going solo will require more patience, but act as a multiplier. In any case, everybody wins. In short, our investment thesis has not changed. We still need three things: 1. Consistent and substantial quarter-over-quarter improvement. 2. Good enough NSCLC data. 3. Nothing critical to happen (severe maintenance issues, severe misguidance, etc.). Long is the way, let's ride. 🤍

@jfais20 @JoseRestonVA Wow surprised to see Jose doesn’t own a single name out of your picks sir

@JoseRestonVA Great job Jose 👏 Green flag= no style drift (sticking to what's working for you)

Current bio holdings in my portfolio: Top 5: $APGE, $RVMD, $ORKA, $LBRX, $CTMX  Mid: $NAMS, $ZEAL (Danish market), $ABVX, $EVMN, $MDGL, $GPCR Bottom: $MPLT, $KYMR, $CRVS, $JANX, $VKTX Other Positions (Swiss-based):Novartis, Roche, Swisscom (redistributed some funds among other Swiss holdings), ABB, Nestle, Galderma, Holcim, Swiss Marketplace Group, Swiss Re Options:$NVO (June $40c),  $SPY (always keeping a hedge - this time May 22nd $700p, in and out) April puts on $PLTR, $ARES, $OWL did not work. They all expired worthless. By end of february, my biotech portfolio had a negative performance . But then March and April (so far) came, and this has reversed to a quite positive return. Several drivers: XBI strong uptrend, outperformance on some top positions  (ORKA, LBRX, etc.), good data readouts (APGE, RVMD), an acquisition (TERN), and opportunistic exits after good data readouts (IDYA). Underperformers in the period (e.g.  ZEAL, GPCR) were  more than offset by outperformers. Overall portfolio's performance is positive YTD including Swiss names and some hedges that worked well. Things could change at anytime due to market conditions. But so far...in the right direction. I am still underinvested in the biotech sector and have very limited exposure to the US market as my mindset about the overall market has not changed. For that reason, I keep a high % of cash, have hedges, and will continue to do opportunistic short-based trades (always via puts).  Keeping flexibility in the event of market turnarounds.

Algo set to difficulty level extreme. Basically spending the whole day trying to fuck you out of your shares before the buy program $kura $qure $sndx $iova

@Biotech2k1 Well when you sell INSM I will know you are serious

@MashReez All biotech must go. Too much buyout FOMO in there.

Sold all my $CRNX today as biotech bubble continues higher. That should get me closer to my 25% minimum weight. I still plan to sell to 100% cash at $XBI $150 and start over after rhe bubble poos. Been a huge year off the lows of last year.

@Biotech2k1 How can it be a bubble ? It’s only $4 from FDA approval and two weeks ago you said it was worth $63. Now you are selling at $40? Head scratcher but it’s your money

@MashReez All things biotech will go into the biggest bubble since 2021.

@christankerfund Crazy bad timing on that CLCO M&A they missed the rally

$FLNG is hot today and up 4% on well above average volume $CCEC also +5%

@csidetrader Congrats !

$NE was the stock I was debating whether to sell or hold due to an 8% dividend on my cost basis. But my analysis determined this was the spot to exit in both my portfolio and my daughters IRA account so I left the sell order intact. Held for over 1 year so long term capital gains

$NE was purchased in this portfolio at the end of Feb/early March on an insider buy signal at 26.98/22.48 for an avg. price of 24.73 but definitely a bad entry point as price went substantially lower in April. Finally breaking out even though $CL_F #oil is dead consolidating.

@mike98572986 LFG !

$qure $clpt Interesting sequence of events hd advocate day today, this Cber news and tomorrow Uniqure on stage with the fda talking about rct and placebo trials? Fun times

@walterkirn Let’s hope he is more kind to the rare disease community. The current admin have been horrifically bad

It's my privilege to know Houman, and he will be terrific in this role. Good news! Trump officials consider physician, a Fox News regular, for top vaccine post - The Washington Post apple.news/AXiVq0k5gTVmsO…

That add looking clutch so far $qure 💥

@MaryBschanck (12) has built highly valuable network of ATCs

$IOVA Here are 11 reasons why I believe $IOVA shareholders may be sitting on a major opportunity: (1) Clear path to profitability leadership has emphasized strong focus on reaching it (2) Full ownership of the global TIL platform no divesting of international assets, keeping long-term value in-house (3) REPL’s second CRL potentially opens the door for greater market share capture (4) Management has previously signaled no intention to cap valuation strong alignment with shareholder upside (5) Lung cancer opportunity is significantly larger than melanoma, with additional indication expansion ahead (6) Patent protection extending into ~2039–2042 supports long-term revenue visibility (7) Strong clinical data over 60% ORR and ~30% complete response in frontline advanced melanoma (lifileucel + pembro combo) (8) Partnership with McKesson expected to expand patient reach and drive revenue growth (9) Elevated short interest potential for upside if sentiment shifts or coverage increases (10) Employee stock options now in the money aligns incentives and boosts internal momentum (11) Technical structure improving transitioning from ~$1.75 base to a pattern of higher highs and higher lows Wishing all IOVA bulls a strong run ahead.

@fugitive4242 @susan_naud_link That’s why I said it would be a steal. Probably would kick off a bidding war between Bmy and Mrk

@MashReez @susan_naud_link Wayne Rothbaums not taking peanuts for this company. His 30 million shares have an average cost of $7. He's fully cooking this platform and selling for 20-30 Billion. Melanoma frontline, NSCLC, Sarcoma on the menu.

@Biotech2k1 Up 17% on no data 😂

Up 17% after hours. finance.yahoo.com/sectors/health…

@lucentionllc @jy201506 I added a small bit to my $iova position out of spite today higher than my avg at $3.67. Hard to imaging the stock traded down on 45 million shares on the CRL news. I think someone manipulated the tape with cheap call options expiring today at $4 strike. Almost 20,000 contracts!

Great work @jy201506 and to others who’ve made similar calls Congrats to the $IOVA bulls 🏆. $REPL RP1 rejection represents a meaningful change to the post-PD1 melanoma landscape

They may pop this over $4 near the close. 20,000 $4 call contracts traded now expiring today. Very suspicious $iova

Insane amount of $4 calls for April 17 being purchased. As soon as market maker is done loading stock is gonna fly. Don’t be fooled by this trickery $iova

@jfais20 Welcome. Strange for iova to be red on the news but nothing surprises me in this market

@MashReez Thx

$repl contribution of components was my primary concern as well